MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI ...
International Clinical Trials Day marked the anniversary of the very first clinical trial conducted by James Lind on board ...
Knowable Magazine reports on a revolutionary CAR T-cell therapy, originally for cancer, now showing promise for autoimmune ...
Some early signs of MS can look like tiredness, but there are other subtle signs that should make one cautious, shares Dr Atampreet Singh. | Health ...
Onlymyhealth on MSN
The 4 types of multiple sclerosis: Symptoms and differences explained
Multiple Sclerosis (MS) is a chronic neurological autoimmune disease of the central nervous system that affects every individual differently. In the case of MS, it attacks the protective covering of ...
Alzheimer’s disease is the most common cause of dementia. In the United States, an estimated 6.9 million adults age 65 and ...
Snowflake disease symptoms vary from person to person - here's what myasthenia gravis and MS actually look like, and why both ...
Autoimmune neurological disorders occur when the body's immune system mistakenly attacks healthy tissues within the brain, ...
Abstract: Battery fault early warning is essential for the safe operation of electric vehicles, yet early-stage faults remain highly concealed and difficult to detect. While traditional threshold ...
Irisin, a hormone released during exercise, appears to directly shield neurons from damage in a mouse model of multiple ...
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results